This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Vaximm Ag. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Holger Siede: Innovator in Recombinant DNA Technology
Introduction
Holger Siede is a notable inventor based in Ronnenberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of novel methods for growing attenuated mutant strains.
Latest Patents
Holger Siede holds one patent that focuses on a unique method for cultivating attenuated mutant strains lacking galactose epimerase activity. This method involves culturing the strain without adding glucose to the medium during fermentation, ensuring that the initial glucose amount is depleted before reaching the stationary phase. The invention also pertains to attenuated mutant strains that can be obtained through this method, including those harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
Career Highlights
Holger Siede is associated with Vaximm AG, a company that specializes in innovative vaccine development. His work at Vaximm AG has positioned him as a key player in the biotechnology sector, contributing to advancements in vaccine technology.
Collaborations
He has collaborated with notable colleagues, including Heinz Lubenau and Renate Janssen, who have also contributed to the field of biotechnology.
Conclusion
Holger Siede's innovative work in recombinant DNA technology and his contributions to vaccine development highlight his importance in the field of biotechnology. His patent reflects a significant advancement that could have a lasting impact on vaccine research and development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile